Ashutosh Upadhyay, Sr Specialist, Oncology at Illumina for India, shared on LinkedIn:
“Unlocking the Power of Genomics in Cancer Care!
A recent prospective study at HCG Hospital profiled 1000 biopsy-proven cancer patients using Illumina TSO500.
Key Highlights of the study:
- 80% of patients had clinically relevant genetic alterations (Tier I & II)
- 47% had druggable gene targets vs. 14% with smaller panels
- 16% had tumor-agnostic immunotherapy biomarkers
- 13.5% showed HRR pathway alterations, including BRCA
- Detected 1,747 genomic alterations, guiding treatment changes in 43% of the cohort.
- Patients reviewed by the Molecular Tumor Board (MTB) showed greater therapy adaptation and improved outcomes.
- At a median 18-month follow-up, 71% of patients were alive, reinforcing the clinical impact of genomics-driven, personalized cancer treatment.
Congratulations to Dr. B S Ajaikumar, Mithua Ghosh and their team for publishing this report!
A great study from India using TSO500 strengthens the case for integrating CGP and MTB discussions into routine oncology practice for better patient outcomes.
